Schering-Plough Teams Up With Huya To Identify Novel Compounds In China
This article was originally published in PharmAsia News
Executive Summary
Schering-Plough susbsidiary Organon and Huya Bioscience International unveiled an agreement Dec. 15 under which Huya will identify and present to Organon drug candidate compounds originating in China for specific therapeutic areas
You may also be interested in...
U.S.-based Huya Bioscience Signs Drug Development Pact With China's Guangzhou Institutes Of Biomedicine
BEIJING - Huya Bioscience International has signed a partnership agreement with the Guangzhou Institutes of Biomedicine and Health on the joint development of innovative compounds that could provide a bridge between GIBH scientists and the global market, according to Huya's senior leadership
U.S.-based Huya Bioscience Signs Drug Development Pact With China's Guangzhou Institutes Of Biomedicine
BEIJING - Huya Bioscience International has signed a partnership agreement with the Guangzhou Institutes of Biomedicine and Health on the joint development of innovative compounds that could provide a bridge between GIBH scientists and the global market, according to Huya's senior leadership
Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets
BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive